Pfizer's (PFE) Germano: Company Still in 'Evaluation Process' on Possible Split
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $24.17 -0.33%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.1%
Revenue Growth %: -1.9%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.1%
Revenue Growth %: -1.9%
Join SI Premium – FREE
Pfizer, Inc. (NYSE: PFE) Geno Germano said the company is still in "evaluation stage" on a breakup. Splitting commercial operations isn't hard, but dividing and reorganizing the supply chain is. The company will have more to say on a split-up later this year.
Geno Germano is President and General Manager, Specialty Care and Oncology at Pfizer. He is presenting at the Goldman Sachs 34th Annual Global Healthcare Conference this morning.
Geno Germano is President and General Manager, Specialty Care and Oncology at Pfizer. He is presenting at the Goldman Sachs 34th Annual Global Healthcare Conference this morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Pfizer (PFE) to Hold
- Warburg Pincus near over $7 billion deal for specialty-pharmacy company PantheRX - WSJ
- Z Squared amends Skycore acquisition letter of intent, drops exclusivity
Create E-mail Alert Related Categories
Insiders' Blog, Management Comments, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
